Quick Facts

• Targeted Use: Relief of symptoms associated with seasonal allergic rhinitis.
• Additional Use: Management of chronic spontaneous urticaria (hives).
• Observed Benefit: Helps reduce nasal symptoms such as sneezing and runny nose.

---

Alergo is an approved therapeutic option for the management of various allergic conditions. Its main purpose is to help provide relief from the symptoms of seasonal allergic rhinitis, commonly known as hay fever. These symptoms may include a runny nose, sneezing, itching of the nose or throat, and watery eyes.

In addition to seasonal allergies, this medication is also indicated for the management of symptoms associated with chronic spontaneous urticaria, or hives. For patients with chronic urticaria, Alergo may support the reduction of skin itching and the appearance of hives.

This medication is also observed to help alleviate symptoms of non-nasal allergic rhinitis, such as itching of the eyes and throat. Alergo is intended to help manage these conditions by addressing the body's response to allergens and supporting overall symptom control.

Eligibility Map: Who can and cannot use Alergo — Official Regulatory Information

The eligibility profile for Alergo (Cetirizine Hydrochloride) is defined by regulatory bodies based on age, physiological status, and pre-existing medical conditions.

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed	Adults and adolescents (ge 12 years); Children aged 6 to 11 years; Children aged 2 to 5 years (often via oral solution form).
Populations for whom use is contraindicated	Patients with known hypersensitivity to Cetirizine, hydroxyzine, or any piperazine derivatives; Patients with End-Stage Renal Disease (CrCl <10 mL/min or eGFR <15 mL/min).
Age-related eligibility rules	Use is not recommended in children under 2 years of age due to insufficient clinical data.
Condition-specific eligibility rules	Patients with mild to moderate renal impairment require a restricted, reduced dosage. Solely hepatic impairment typically requires no adjustment, but combined hepatic and renal impairment does.
Pregnancy and lactation eligibility status	Use during pregnancy is advised only if clearly needed. Use is not recommended during lactation as the substance is excreted in breast milk.
Eligibility-related restrictions	Use must be with caution in patients with a predisposition to urinary retention or those who are epileptic or at risk of convulsions.

Connection to the Overall Eligibility Profile

The regulatory documents define who can and cannot use the medicine primarily based on the risk of allergic reaction or the patient's capacity to clear the drug from the body. Patients with severe kidney failure are explicitly prohibited from using the medicine. Other populations, such as those with less severe renal impairment or certain co-morbidities, are eligible for use only under defined restrictions, as stated in official prescribing information.

Interactions with Other Medicines and Products

Alergo (fexofenadine) is generally associated with fewer significant drug interactions compared to older antihistamines. However, regulatory documents identify specific product classes and patient conditions that may affect its concentration in the body, which is primarily cleared without hepatic metabolism but relies on transporter proteins like P-glycoprotein (P-gp).

Documented Pharmacokinetic Interactions

• Macrolide Antibiotics: Concomitant use with certain macrolide antibiotics, specifically erythromycin and ketoconazole, can increase the plasma concentrations of fexofenadine. This interaction is attributed to the inhibition of the P-gp transporter, which reduces the elimination and increases the absorption of fexofenadine. While the resulting plasma levels are typically within the safety range seen in clinical trials, regulatory bodies advise consultation with a healthcare professional before combining these medicines.

• Antacids: The absorption of fexofenadine is significantly reduced when taken with antacids containing aluminum and magnesium hydroxide. This reduction in effectiveness can be minimized by separating the administration of Alergo and these antacids by a minimum of two hours.

• Fruit Juices: Taking fexofenadine with grapefruit, orange, or apple juice is not recommended, as these beverages can substantially decrease the absorption of the drug via Organic Anion-Transporting Polypeptide (OATP) inhibition, potentially reducing its effectiveness.

Population-Specific Constraints

Fexofenadine is largely excreted unchanged by the kidneys. Therefore, patients with kidney disease (renal impairment) and elderly individuals, who often have reduced renal function, should consult a doctor before use, as they may be at a greater risk of experiencing elevated drug concentrations and potential toxic reactions. A dose adjustment may be necessary in these populations.

Selective H1 -Receptor Antagonism in the Periphery

The drug's primary action is the selective antagonism of the Histamine H1 -receptor , functioning as an inverse agonist. This mechanism reduces the ability of the inflammatory mediator histamine to activate its target, influencing the early molecular steps that shape the physiological response. This interaction is concentrated on peripheral receptors, indicating a primary influence on systemic pathways outside of the central nervous system.

Influence on Capillary Permeability and Fluid Dynamics

By blocking the H1 -receptor on vascular endothelial cells, the drug directly inhibits the histamine-mediated cascade that governs increased capillary permeability and local vasodilation. This inhibits the histamine-mediated increase in leakage of fluid and proteins from the microvasculature into surrounding tissues. This action influences processes driven by histamine release, resulting in reduced tissue fluid accumulation.

Influence on Sensory Signaling Pathways

The mechanism extends to the sensory nervous system by blocking H1 -receptors located on the terminals of afferent nerve fibers. This modifies the signal transduction, reducing histamine's ability to stimulate the nerve endings that transmit the sensation of pruritus. This influence affects neural responses within the sensory pathway.

Alergo is approved for use via two primary routes of administration: Oral (including tablets, solutions, and chewable forms) for routine management, and Intravenous (IV) for specific acute conditions in the hospital setting.

---

Standard Administration and Regimens

The standard oral dosing regimen for adults and adolescents (12 years of age and older) typically ranges from 5 mg to 10 mg, administered once daily. The maximum recommended daily intake for this population is 10 mg. Administration is flexible and permitted with or without food. If a scheduled oral dose is missed, official guidance generally directs users to take the subsequent dose at its usual time, rather than attempting to double the dose. The IV injectable form must be administered as an intravenous push over a period of 1 to 2 minutes.

---

Population-Specific Use and Dosage Forms

Official labeling stipulates specialized dosing and administration practices for certain populations. For children aged 6 to 11 years, the oral dose is typically 5 mg or 10 mg once daily. The use of a pediatric oral solution or syrup is required for children under 6 years, as the tablet form does not allow for the necessary precise 2.5 mg dose adjustments. Furthermore, dose modification is mandatory for patients with compromised renal function, where the frequency of administration must be reduced—for example, to 5 mg once every two days in cases of severe impairment. No dose adjustment is typically specified for solely hepatic impairment.

Research evidence / Overview of studies for Alergo

---

Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

The research foundation for Alergo’s use in the clinical evaluation of symptoms associated with seasonal allergic rhinitis relies heavily on short-term Randomized Controlled Trials (RCTs). Researchers primarily measured outcomes within predefined symptom scales, such as the Total Symptom Scores (TSS), which include metrics for sneezing, runny nose, and ocular itching. These studies generally examined data collected over short time intervals, typically lasting from one to four weeks. Studies report how symptoms evolved in the observed populations compared to the placebo.

---

Evidence for Use in Chronic Spontaneous Urticaria (Hives)

Alergo was evaluated in studies for its use in the clinical evaluation of symptoms associated with chronic spontaneous urticaria (CSU), or chronic hives. The research structure includes RCTs, systematic reviews, and meta-analyses. Studies primarily assessed outcomes describing episodic or acute changes by using combined metrics like the Urticaria Activity Score (UAS), as well as separate measurements for the severity of itching (pruritus) and the number/size of the welts (weals). The long-term effects are not fully established because the core RCTs generally focus on short- to intermediate-term follow-up.

---

Extended-Duration Studies and Follow-Up

The majority of the published evidence was studied for short-term symptom outcomes. Extended-duration studies, sometimes referenced in regulatory reviews, have been used in research exploring fluctuating or unstable symptoms, particularly for chronic conditions like perennial rhinitis and chronic urticaria. These studies provide context, but research does not determine whether an individual will respond similarly regarding the sustained nature of the changes.

---

Research Gaps and Areas of Uncertainty

The research highlights what is known—and what is still uncertain—about Alergo. Key limitations include the fact that long-term effects are not fully established beyond the short- to intermediate-term study periods that most trials employ. Furthermore, comparative evidence is lacking across all available non-sedating antihistamine classes for every single indication. Sample sizes were modest in some of the subgroup analyses, particularly for the younger pediatric cohorts.

Key Studies & References

1. Cetirizine for allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials

Common questions about Alergo (FAQ)

Q: Does Alergo affect my ability to drive or operate machinery?

According to the official product information, Alergo may cause drowsiness in some people, which could potentially impair the ability to drive or use heavy machinery. Patients are advised to understand their individual reaction to this medicine before deciding to engage in activities requiring full attention. Regulatory documents recommend caution.

Q: Can I take Alergo if I am pregnant or breastfeeding?

Studies and official information indicate that use of Alergo during pregnancy or while breastfeeding is generally not recommended due to limited data. There is not enough information available on its effects on an unborn baby or if the drug passes into breast milk in sufficient quantities. Consultation with a healthcare professional is necessary to evaluate the risks and benefits for your specific situation before use.

Q: Is there an age limit for taking Alergo?

Regulatory documents state that Alergo is not approved for use in children under the age of six. The official product information specifies its use is intended for adults and children six years of age and older. The current official guidance should always be consulted for complete age criteria.

Q: How quickly should I expect Alergo to start working for my symptoms?

Official product information indicates that Alergo is generally absorbed quickly after administration. Clinical data and product labels indicate the onset of action is often within one hour after administration. It is important to remember that the exact time until the medicine takes full effect can vary significantly between individuals.

How to Store and Dispose of Alergo (Cetirizine Hydrochloride)

Official regulatory documents define specific storage and disposal requirements for Alergo to maintain product stability and ensure safety.

Storage Requirements

Alergo tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container and should remain tightly closed, protected from excessive moisture and excessive heat. The liquid oral solution form of the medicine must not be frozen. As a mandatory regulatory requirement, Alergo must be stored out of the reach of children.

Disposal Instructions

Unused or expired Alergo should be disposed of through a drug take-back program or mail-back option, when available. If those methods are not accessible, the medicine is not to be flushed down the toilet. Instead, it must be mixed with an undesirable substance, sealed in a bag, and then discarded in the household trash, following official disposal guidance.